Save time and jump to the most important pieces.
Date | Price Target | Rating | Analyst |
---|---|---|---|
12/20/2021 | $9.00 | Speculative Buy | Benchmark |
SC 13D - HeartBeam, Inc. (0001779372) (Subject)
SC 13D - HeartBeam, Inc. (0001779372) (Subject)
SC 13D - HeartBeam, Inc. (0001779372) (Subject)
4 - HeartBeam, Inc. (0001779372) (Issuer)
4 - HeartBeam, Inc. (0001779372) (Issuer)
3 - HeartBeam, Inc. (0001779372) (Issuer)
Received FDA Clearance for the HeartBeam System – an At-Home, High-Fidelity Heart Monitoring Technology Commenced Early Access Program to Attain Key Insights and Establish Sales Funnel in Preparation for Commercialization Submitted 510(k) Application to FDA for Groundbreaking 12-lead Electrocardiogram (ECG) Synthesis Software Gross Proceeds of ~$11.5 Million from Public Offering and Over-Allotment Option to Fund Near-Term Milestones Management to Host Webcast and Conference Call Today at 4:30 p.m. ET HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, has reported its financial and operation
HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, today announced that CEO Robert Eno and CFO Timothy Cruickshank will be participating in the following upcoming conferences in Dana Point, CA. 37th Annual Roth Conference being held at The Laguna Cliffs Marriott Resort & Spa, March 16-18, 2025 LSI USA '25 Conference being held at the Waldorf Astoria, Monarch Beach, March 17-21, 2025 To schedule a one-on-one meeting with HeartBeam management, please contact your conference representative or email your request to [email protected] or call Chris Tyson at (949) 491-8235. About HeartBeam, Inc. HeartB
HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, will hold a conference call on Thursday, March 13, 2025 at 4:30 p.m. Eastern time to discuss its results for the fourth quarter and full year ended December 31, 2024, and will be providing updates on regulatory initiatives, commercial-readiness activities and anticipated milestones. A press release detailing these results will be issued prior to the call. HeartBeam CEO Robert Eno and CFO Timothy Cruickshank will host the conference call, followed by a question-and-answer period. The conference call will be accompanied by a presentation, which can be
Benchmark initiated coverage of BioTelemetry with a rating of Speculative Buy and set a new price target of $9.00
4 - HeartBeam, Inc. (0001779372) (Issuer)
4 - HeartBeam, Inc. (0001779372) (Issuer)
10-K - HeartBeam, Inc. (0001779372) (Filer)
8-K - HeartBeam, Inc. (0001779372) (Filer)
8-K - HeartBeam, Inc. (0001779372) (Filer)
First cable-free, ambulatory ECG that captures the heart's electrical signals from three distinct directions for high-fidelity data collection and advanced diagnostics Patients can have the credit card-sized device with them at all times, ready to record an ECG whenever they feel symptoms and reduce delays in care Company to initiate Early Access Program to gain important patient and physician feedback on the use of the system in preparation for commercial launch HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, today announced that the US Food and Drug Administration (FDA) has granted 510(k) cl
Industry leader brings extensive experience in developing go-to-market strategies for breakthrough products and delivering growth Founder and current CEO Branislav Vajdic named President to focus on advancing the Company's groundbreaking vector-based technology for heart health, including AI applications HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful insights wherever the patient is, announced that Robert Eno has been appointed Chief Executive Officer (CEO), effective Monday, October 21, 2024. The seasoned MedTech executive joined HeartBeam as President in January 2023 and will lead as the Company continues to work
Industry Leader, Former Head of Data Science at Verily (Google Life Sciences) and Globally Respected Authority on Artificial Intelligence (AI) Applications in Biosensor Technologies Dr. Myers to Drive Innovation and Strategic Growth as HeartBeam Advances and Expands its AI Capabilities HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights wherever the patient is, announced the appointment of Lance Myers, PhD, a pioneer in digital health data analytics and body-worn biosensor technologies, as Chief Artificial Intelligence (AI) Scientist. In this newly created position, Dr. Myers will play a pivotal role in gu
HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, will hold a conference call on Thursday, March 13, 2025 at 4:30 p.m. Eastern time to discuss its results for the fourth quarter and full year ended December 31, 2024, and will be providing updates on regulatory initiatives, commercial-readiness activities and anticipated milestones. A press release detailing these results will be issued prior to the call. HeartBeam CEO Robert Eno and CFO Timothy Cruickshank will host the conference call, followed by a question-and-answer period. The conference call will be accompanied by a presentation, which can be
Continued Clinical and Regulatory Progress on the HeartBeam System Key Appointments to Management Team Completed as Part of Planned Evolution in Preparation for US Commercialization Strengthening Clinical Evidence Base, with Two Additional Studies to be Presented at the American Heart Association Conference in November 2024 Management to Host Webcast and Conference Call Today at 4:30 p.m. ET HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, has reported its financial and operational results for the third quarter ended September 30, 2024. Third Quarter & Subsequent 2024 Operational Highlights
HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights wherever the patient is, will hold a conference call on Thursday, November 7, 2024 at 4:30 p.m. Eastern time to discuss its results for the third quarter ended September 30, 2024, and will be providing regulatory updates, reviewing ongoing initiatives, and anticipated milestones. A press release detailing these results will be issued prior to the call. HeartBeam CEO Robert Eno, Founder and President Branislav Vajdic, PhD, and CFO Timothy Cruickshank will host the conference call, followed by a question-and-answer period. The conference call will be accompa